|
|
Type of Company:
Type:
|
Company
|
Ownership: |
Publicly Traded (SRRA, NASDAQ) |
Company Size: |
20-49 Employees In BC (50-99 Total)
20-49 In BC (50-99 Total)
|
Year Founded: |
2003 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Profile Views: |
1,500 Company Profile Views |
|
|
|
Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. We are an ambitious company, oriented towards achieving the successful registration and commercialization of our drug candidates and we have a world-class management team with a proven track record of success in oncology drug development. |
|
|
Date |
Type |
Amount |
Investors |
Nov 8, 2019 |
Private Placement |
$103 Million CAD |
underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with expected gross proceeds to Sierra Oncology of $103 million. Jefferies is acting as the sole book-running manager for the offering. Oppenheimer & Co. is acting as lead manager for the offering. |
Nov 26, 2019 |
Private Placement |
$103 Million CAD |
The public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, provided Sierra Oncology with net proceeds of approximately $98.0 million, after deducting underwriting discounts and commissions and offering expenses |
Date |
Type |
Amount |
Investors |
Nov 8, 2019 |
Private Placement |
$103M CAD |
underwritten public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, with expected gross proceeds to Sierra Oncology of $103 million. Jefferies is acting as the sole book-running manager for the offering. Oppenheimer & Co. is acting as lead manager for the offering. |
Nov 26, 2019 |
Private Placement |
$103M CAD |
The public offering of Series A convertible preferred stock, together with Series A warrants and Series B warrants, each to purchase shares of common stock, provided Sierra Oncology with net proceeds of approximately $98.0 million, after deducting underwriting discounts and commissions and offering expenses |
|
|
|
|
|
Dec 17, 2020
|
Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts
|
|
Nov 18, 2020
|
Sierra Oncology Reports Third Quarter 2020 Results
|
|
Sep 8, 2020
|
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
|
|
Jun 1, 2020
|
Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib
|
|
Mar 5, 2020
|
Sierra Oncology Reports 2019 Year End Results
|
|
Feb 6, 2020
|
Sierra Oncology Issues Stock to Pharma Giant Gilead Sciences for Reduced Royalty Rates, Converts Preferred Shares to Common from Recent Financing
|
|
Jan 22, 2020
|
Vancouver-based Sierra Oncology Announces 1-FOR-40 Reverse Stock Split
|
|
Nov 26, 2019
|
Vancouver-based Sierra Oncology Announces Closing of $103 Million Financing and Changes to its Board of Directors
|
|
Nov 22, 2019
|
Vancouver-based Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial
|
|
Nov 15, 2019
|
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib
|
|
|
1 - 10 of 29 results
|
|
 |
|
|
|
Share This Company Profile |
|
|
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
Employers
Post Job Listings
Advertise
